Beat The Denominator

Do not chase Nebius (NBIS) at its current all-time high due to extreme short-term volatility, but keep it on your radar for a very long-term position. Wait for aggressive market sell-offs or bear attacks to scoop up NBIS at a discount, as the stock has a history of overcorrecting. Use the strong execution of Micron (MU) as a benchmark to evaluate how effectively infrastructure suppliers handle early customer prepayments. Closely monitor the deployment timeline of the 5,000-megawatt capacity pipeline for NBIS through 2027 to ensure smooth operational growth. Finally, watch developments in the autonomous vehicle sector—led by Tesla (TSLA)—to accurately gauge the hidden, undervalued potential of the AV Ride subsidiary.

Capitalize on the recent post-earnings dip to buy shares of Hims & Hers Health (HIMS) around $29.50, viewing this pullback as an attractive entry point for a long-term holding.

The company is experiencing rapid scaling driven by strong subscriber growth and expanding high-margin specialties like testosterone replacement therapy.

Look for an upcoming catalyst this fall with the launch of new peptide offerings supported by their newly acquired U.S. manufacturing facility.

The business model benefits from a cash-pay system that bypasses insurance hurdles and leverages artificial intelligence for personalized healthcare treatments across its 3 million subscribers.

Investors should overlook short-term gross margin compression and GAAP net losses, recognizing them as strategic growth investments for this subscription-based healthcare platform.

Anticipate near-term downward or sideways pressure on MicroStrategy Inc. (MSTR) as the company continues diluting common stock to reach its rumored $5 billion USD cash reserve goal.

Investors bullish on Bitcoin should note that MSTR is currently prioritizing balance sheet safety and STRC support over aggressive new crypto accumulation.

Monitor STRC for a continued recovery toward its target price of $100, supported by management's recent buybacks and proactive market signaling.

Recognize that buying MSTR right now means tying your capital to a defensive corporate strategy during a volatile period for cryptocurrency markets.

Only enter MSTR positions if you are comfortable with potential equity dilution while waiting for Bitcoin prices to break out from the $65,000 range.

Wait to buy Hims & Hers Health (HIMS) at $31 until after earnings, targeting a 20% narrative-driven pullback to accumulate shares at a discount.

Capitalize on Nebius (NBIS) trading at $187 by treating short-seller pressure as a buying opportunity for this high-growth AI infrastructure play with a $51 billion pipeline.

Exercise patience with Nebius (NBIS) by avoiding pre-earnings bets and waiting for short-term volatility to secure better entry points.

Target CoreWeave (COREW), valued at an $82 billion market cap, as a top pure-play NeoCloud candidate if a broader market pullback creates a 30% discount.

Accumulate Bitcoin (BTC) near the $65,000 support level as a stabilizing foundation for broader crypto and risk asset recovery.

Target a breakout toward $70,000 to $80,000 to capitalize on high-beta upside for correlated equities like MicroStrategy (MSTR).

Use MicroStrategy (MSTR) as an amplified proxy for Bitcoin, keeping a close eye on its net asset value multiple to time your entries effectively.

Buy STRC below its $100 par value to lock in a compelling 12% yield that becomes increasingly attractive as Treasury yields decline.

Consider Seta trading near $99 for its higher 13% yield and simpler balance sheet as it rapidly approaches par value ahead of peers.

Investors should consider accumulating shares of Real Brokerage (REAX) as a long-term holding due to its disruptive online model and attractive valuation compared to peers like HIMS and Nebius. Watch for the critical shareholder vote on August 14 regarding the planned REMAX acquisition, which is expected to double the company's size and revenue by the second half of 2026. Keep a close eye on macroeconomic factors, specifically 10-year Treasury yields and mortgage rates, as these will heavily influence short-term price volatility. Capitalize on the recent 32% five-day market rebound by using any dips driven by interest rate fears as buying opportunities. Finally, monitor ongoing agent recruitment metrics to ensure the firm continues capturing market share from legacy competitors.

Consider Hims & Hers (HIMS) as the premier sector leader for high-growth exposure to the telehealth megatrend, driven by its dominant scale and projected revenue growth of 34% to 40%.

Alternatively, view LifeMD (LFMD) as a high-risk, deep-value turnaround play or speculative acquisition target given its dirt-cheap price-to-sales multiple of 0.6 and built-out insurance-reimbursement infrastructure.

Investors in LFMD should closely monitor management's ability to achieve positive EBITDA by the end of the year without causing further deceleration from its modest 8% projected 2026 revenue growth.

Evaluate LFMD's unique insurance-accepting model as a potential defensive moat against pure-play competitors, especially regarding future Medicare tailwinds for GLP-1 medications.

Track upcoming guidance updates for HIMS following recent acquisitions like Eucalyptus to ensure the company continues outpacing smaller telehealth peers.

Capitalize on the recent 13% drop in Oscar Health (OSCR) by treating it as a compelling long-term hold, given its massive revenue beats and dirt-cheap valuation. Ignore Wall Street's overreaction to standard medical loss ratio cycles and view OSCR as fundamentally disconnected from its short-term price sell-off. Accumulate shares of Celsius Holdings (CELH) following its recent 17% post-earnings drop, which was driven by temporary inventory noise rather than core business deterioration. Leverage CELH's deep value status, boasting a stellar Rule of 40 score of 61 and strong market share gains against legacy competitors Red Bull and Monster. Use the current summer market illiquidity to buy both OSCR and CELH at steep discounts for significant multi-quarter upside.

Buy Zeta Global Holdings Corp. (ZETA) as a compelling medium-term growth play, supported by its proprietary global tracking moat, enterprise-level AI partnerships, and an attractive valuation relative to its rapid expansion. Accumulate TransMedics Group, Inc. (TMDX) for long-term turnaround potential as it targets $2 billion in revenue by 2032, though investors should remain cautious of near-term Medicare reimbursement risks. Position in SoFi Technologies, Inc. (SOFI) as a leveraged trade on lower interest rates, where a drop in borrowing costs could trigger a major valuation re-rating. Monitor digital credit instruments like STRC and MicroStrategy (MSTR) for recovery plays as Bitcoin sentiment stabilizes and Treasury yields decline.

Consider building a long-term position in Zillow Group (ZG), which is currently trading down roughly 65% to 66% from its peak due to macroeconomic interest rate pressures rather than weak business fundamentals.

Exercise caution and wait for upcoming earnings results before making a heavy investment, as summer mortgage rates near 7% may have negatively impacted recent home sales.

Monitor macroeconomic indicators closely and look for 30-year mortgage rates to decline toward 4% before expecting a major market turnaround.

As the housing market eventually normalizes, successful execution by Zillow Group (ZG) could drive significant revenue acceleration and potential 3x to 5x stock appreciation over a longer investment horizon.

Maintain similar patience with deeply discounted real estate plays like REACs, ensuring you tie any new trades strictly to an eventual drop in interest rates and improved housing market liquidity.

Investors should expect continued volatility and a "slow bleed" in Bitcoin (BTC) and related assets while the current bear market persists.

Long-term investors can look past short-term fear and minor news events, as historical precedent suggests that bear markets are temporary.

Watch for a recovery in Bitcoin (BTC) back toward the $80,000 price target, which serves as the primary catalyst for the broader crypto ecosystem.

MicroStrategy (MSTR) operates as a leveraged proxy for Bitcoin (BTC) and will only see meaningful stock recovery once the underlying cryptocurrency rebounds.

Ignore minor corporate noise like small balance sheet adjustments or tax-loss selling, focusing instead on the macro recovery timeline expected within the next couple of months.

Accumulate shares of Meta Platforms (META) as it currently trades as the cheapest Magnificent 7 stock, sitting roughly 20% cheaper than NVIDIA (NVDA).

Take advantage of NVIDIA’s favorable valuation near the $200 price level, as its fabless business model allows for rapid scaling during the ongoing AI boom.

Target Micron Technology (MU) around the $820 level as a top hardware pick, supported by an ultra-low P/E ratio of 4.5 to 5 and a shift away from pure cyclicality.

Invest in Nebius (NBIS) while it trades under the $200 threshold, capitalizing on its temporary valuation dip and multi-billion-dollar enterprise contracts.

Avoid overvalued AI hardware plays like Advanced Micro Devices (AMD) and Broadcom (AVGO) until their valuation multiples drop to align more closely with industry peers.

Accumulate Bitcoin (BTC) near the $63,000 support level while monitoring for geopolitical de-escalation in the Middle East as a catalyst for a relief rally.

Watch for STRC to break the psychological $90 resistance level—currently trading at $89.50—to signal a recovery toward 100 before the asset resumes aggressive buying.

Keep a close eye on the 30-year Treasury yields, as high borrowing costs will continue to pressure digital credit instruments like STRC.

Consider utilizing regulated ETF wrappers like iBit or equity proxies like MicroStrategy (MSTR) to gain exposure while avoiding self-custody risks associated with hardware wallets.

Expect near-term stagnation for MicroStrategy (MSTR) and Bitcoin (BTC) near $64,700 as management halts token purchases to fortify cash reserves by $500 million. Because MSTR stock currently correlates 1:1 with the iShares Bitcoin Trust ETF (IBIT) due to common stock dilution, avoid aggressive buying until broader macroeconomic trends improve. Watch for a recovery in the digital credit "Stretch" instrument targeting $100, backed by an available $975 million buyback authorization. With macro headwinds like the 10-year Treasury yield near 4.7% creating fierce competition for credit, wait for the Federal Reserve to signal interest rate cuts before entering new positions. Patient investors should monitor cooling inflation and easing geopolitical tensions as the primary catalysts for the next sustainable breakout in risk assets.

Capitalize on the recent macro-driven sell-off in Nebius (NEBIUS), which is down 50% from its June peak despite secure enterprise contracts worth billions with Microsoft and Meta. View the recent drop in Hims & Hers Health (HIMS) as a temporary buying opportunity, because the pending FTC lawsuit will likely take until 2030 or 2031 to resolve while its GLP-1 and international catalysts ramp up. Accumulate shares of SoFi Technologies (SOFI) during market-wide pullbacks, as its consistent earnings beats and a strong Rule of 40 score of 67 indicate the current flat stock price is disconnected from its robust fundamentals. Use these broader market sell-offs to build positions in these discounted growth names, keeping in mind that near-term volatility and macro fears may persist. Ensure you align your entry points with a medium-to-long-term investment horizon to ride out any lingering headline risks and sentiment-driven dips.

Accumulate shares of Nebius (NBIS) around the $1.70 pullback level to capitalize on its massive $40 billion AI infrastructure backlog and discounted neocloud valuation. Buy Micron Technology (MU) while it trades at a cheap forward P/E of 4x to 5x earnings, as the market misprices its transition into a structural AI and robotics memory supplier. Purchase NVIDIA (NVDA) below $200 to capture an expected 62% revenue growth rate backed by its dominant CUDA platform and AI market leadership. Take advantage of the recent sell-off in Hims & Hers Health (HIMS) within the $27–$29 range to secure a high-growth, recession-resistant healthcare subscription model with over 2 million recurring subscribers. Finally, buy Meta Platforms (META) as the cheapest Magnificent Seven stock, though investors should exercise caution around upcoming earnings due to potential volatility over AI spending.

Expect near-term weakness in MSTR common stock while the company continues issuing shares to support its digital credit initiatives. Watch for Bitcoin to break out from its current $65,000 stagnation range toward the high $70,000s or low $80,000s before entering a sustained recovery trade. Monitor preferred stock STRC for larger buybacks exceeding the initial $25 million deployment if prices drop further. Factor in broader macroeconomic headwinds, specifically the 10-year Treasury yield touching 4.70%, when evaluating fixed-income and preferred products. Exercise patience through the summer months, anticipating a return of market momentum and higher activity levels by September.